- Home
- AVTX vs GANX Comparison
AVTX vs GANX Comparison
Compare AVTX & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- GANX
- Stock Information
- Founded
- AVTX 2011
- GANX 2017
- Country
- AVTX United States
- GANX United States
- Employees
- AVTX N/A
- GANX N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- GANX Health Care
- Exchange
- AVTX Nasdaq
- GANX Nasdaq
- Market Cap
- AVTX 57.4M
- GANX 57.9M
- IPO Year
- AVTX 2015
- GANX 2021
- Fundamental
- Price
- AVTX $4.41
- GANX $1.86
- Analyst Decision
- AVTX Strong Buy
- GANX Strong Buy
- Analyst Count
- AVTX 6
- GANX 5
- Target Price
- AVTX $34.20
- GANX $8.20
- AVG Volume (30 Days)
- AVTX 62.6K
- GANX 226.2K
- Earning Date
- AVTX 05-12-2025
- GANX 05-14-2025
- Dividend Yield
- AVTX N/A
- GANX N/A
- EPS Growth
- AVTX N/A
- GANX N/A
- EPS
- AVTX N/A
- GANX N/A
- Revenue
- AVTX $441,000.00
- GANX N/A
- Revenue This Year
- AVTX N/A
- GANX N/A
- Revenue Next Year
- AVTX N/A
- GANX N/A
- P/E Ratio
- AVTX $0.59
- GANX N/A
- Revenue Growth
- AVTX N/A
- GANX N/A
- 52 Week Low
- AVTX $3.39
- GANX $0.89
- 52 Week High
- AVTX $16.00
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- AVTX 45.63
- GANX 45.23
- Support Level
- AVTX $3.43
- GANX $1.80
- Resistance Level
- AVTX $4.03
- GANX $1.85
- Average True Range (ATR)
- AVTX 0.34
- GANX 0.12
- MACD
- AVTX 0.09
- GANX -0.01
- Stochastic Oscillator
- AVTX 70.47
- GANX 20.00
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.